Skip navigation

Vaccine Production:

Potential Engineering Approaches to a Pandemic

Conference Program

NEW! Speaker presentations are posted on this page. An archive of the conference webcast is also available for viewing: Webcast

To download files, right click and select "save target as" to your desktop or other folder.

Monday, April 10

Registration and light refreshments, 8:00 am
Opening Remarks, 8:45 am
Arthur Heuer, PhD, DSc, Case Western Reserve University
John Anderson, PhD, Case Western Reserve University
William Wulf, PhD, National Academy of Engineering
A National Perspective on Pandemic Influenza Preparedness, 9:00 am
Bruce Gellin, MD, MPH, Director National Vaccine Program Office
Department of Health and Human Services
Keynote Address, 9:15 am
Pandemic Influenza: A Global Perspective,
Klaus Stöhr, PhD, Head, WHO Influenza Team
Presentation (Adobe PDF, 747 KB)
Keynote Address, 10:15 am
Scientific Methods Underpinning Policy Formulation for an Influenza Pandemic,
Roy Anderson, FRS, FMEDSCI
Professor of Epidemiology, Imperial College, London, UK
Presentation (MS PPT, 23 MB)
Break, 11:10 - 11:30 am
Accelerated Introduction of Pharmaceuticals: The Baseline, 11:30 am
Patrick Scannon, MD, PhD
Chief Scientific and Medical Officer, Xoma, Ltd.
Presentation (MS PPT, 3.6 MB)
Presentation in Adobe PDF (PDF, 1.1 MB)
Lunch, 12:00 - 1:15 pm
Egg-based Influenza Vaccine Production - 30 Years of Commercial Experience and our Future Expectations for Cell Culture, 1:15 pm
James T. Matthews, PhD
Senior Director, Public Policy, Science and Health Policy,
sanofi pasteur, US
Presentation (MS PPT, 12.9 MB)
Cell-culture based Vaccine Production: Technological Options, 2:00 pm
Rino Rappuoli, PhD
Chief Scientist, Chiron Vaccines Research
Presentation (MS PPT, 16.5 MB)
Cell-culture based Vaccine Production: Engineering Bottlenecks, 2:30 pm
Etienne Malhaise
Manager of TS Process Biotech, GSK Biologicals
Presentation (MS PPT, 2.3 MB)
Regulation of Vaccines: Challenges and Opportunities, 3:00 pm
Norman W. Baylor, PhD
Director, Office of Vaccines Review and Research, CBER
Food and Drug Administration
Presentation (MS PPT, 508 K)
Break, 3:40 - 4:00 pm
Panel Discussion, 4:00 - 5:00 pm
Gary Taubes, Moderator
Reception, 5:00 - 6:00 pm

Tuesday, April 11

Registration, 8:00 am
Opening Remarks, 8:25 am
Surge-capable Peptide Therapeutics and Vaccines, 8:30 am
Michael Callahan MD, DTM&H
Division of Infectious Diseases, Massachusetts General Hospital
Program Manager, Avian Influenza Surveillance, U.S. Dept of State, Office of Cooperative Threat Reduction and Defense Science Office/DARPA
Presentation (MS PPT, 4.9 MB)
Alternative Methods of Vaccine Production, 9:00 am
Alan Shaw
President and CEO, VaxInnate
Presentation (MS PPT, 3.8 MB)
A High-Volume, Cost-Effective Microparticle-Based Vaccine Production Process, 9:45 am
William L. Warren, PhD
CEO, VaxDesign Corporation
Presentation (MS PPT, 8.5 MB)
Migration of Monocytes in a Collagen Cushion (Windows Media File, 4.8 MB)
VaxDesign AIS model (Windows Media File, 5.8 MB)
A Microbial Expression System as a Possible Route to Antigen Production for Use as Vaccines, 10:15 am
Lada Rasochova, PhD, R&D Group Leader
Dowpharma - Vaccines
Presentation (MS PPT, 15.6 MB)
Break, 10:45 - 11:15 am
Facility Design & Operational Considerations for the Implementation of Single-Use Disposables in Pandemic Influenza Vaccine Manufacturing, 11:15 am
Kim Nelson, PhD
Senior Associate and Director, Biopharm Services, CRB Consulting Engineers
Presentation (MS PPT, 20 MB)
Downstream Issues: Vaccine Formulation and Sterile Filling Issues, 11:45 am
Shawn Knopp, PhD
Project Manager, Baxter BioPharma Solutions
Michael J. Akers, PhD
Senior Director, Pharmaceutical Research and Development,
Baxter BioPharma Solutions
Presentation (MS PPT, 13.9 MB)
Baxter BioPharma Solutions Manufacturing (Windows Media File, 25 MB)
Lunch, 12:15 - 1:30 pm
Paving the Way to Process Understanding: Improving Manufacturing Performance, and Developing Quality Excellence by using Process Analytical Technology (PAT) in Vaccine Production, 1:30 pm
Ingrid Maes
Consultant, Innovative Technologies
Siemens AG, Competence Center Pharmaceutics
Presentation (MS PPT, 4 MB)
Adapting Industry Practice for Rapid, Large Scale Manufacture of Pharmaceutical Proteins, 2:00 pm
David Estell, PhD
Vice President of Technology, Genencor International
Presentation (MS PPT, 912 K)
Development of a Low Cost Fermentation and Recovery Process for a Commodity Polymer: Nodax™ Polyhydroxyalkanoate, 2:30 pm
Phillip R. Green, PhD
Procter & Gamble Chemical
Presentation (MS PPT, 576 K)
Accelerated Introduction of Materials in the Aerospace Industry, 3:00 pm
S. Eric Cregger
Associate Technical Fellow, The Boeing Company
Presentation (MS PPT, 6.2 MB)
Break, 3:30 - 4:00 pm
Panel Discussion: Next Steps, 4:00 pm
Gary Taubes, Moderator

Vaccine Production: Potential Engineering Approaches to a Pandemic
April 10-11, 2006

Conference Information: email Arthur Heuer at arthur.heuer@case.edu

Copyright © 2006 Northern Ohio Steering Group

If you can read this message you probably are using a browser that is out dated.
Your internet browsing experience will improve by simply upgrading your browser
to the current version.